# US 2021/0330661 A1 · Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330661 A1
- Document ID: US20210330661A1
- Status: Published application
- Kind: A1
- Application number: 17/237,335
- Filed: 2021-04-22
- Published: 2021-10-28
- Earliest claimed: 2020-04-23
- Assignees: China Medical University
- Applicants: China Medical University
- Inventors: Mien-Chie Hung; Yeh Chen; Wen-Hao Yang; Chia-Shin Yang; Yu-Lin Hung; Yu-Quan Wang; Yi-Zhen Chou; Mei-Hui Hou; Chia-Ling Tsai; Bao-Yue Huang; Chian-Fang Hung
- Web page: https://patentgrep.com/patent/US20210330661A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.

## Claims

### Claim 1

A method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell, comprising:
contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sufficient concentration of tafenoquine has a half maximal effective concentration value (EC50) equal to or larger than 2.5 μM.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sufficient concentration of boceprevir ranges from 4 μM to 15 μM.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sufficient concentration of narlaprevir ranges from 8 μM to 40 μM.

### Claim 5 (depends on 1)

The method of claim 1, further comprising:
contacting the cell with a sufficient concentration of remdesivir.

### Claim 6

A method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2, comprising:
contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sufficient concentration of tafenoquine ranges from 30 μM to 500 μM.

### Claim 8 (depends on 6)

The method of claim 6, wherein the sufficient concentration of boceprevir has a half-maximum inhibitory concentration (IC50) of 15.2±3.3 μM.

### Claim 9 (depends on 6)

The method of claim 6, wherein the sufficient concentration of narlaprevir has a half-maximum inhibitory concentration (IC50) of 40.8±4.6 μM.

### Claim 10

A medical composition for use in a treatment of an infection of SARS-CoV-2, comprising:
a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir.

### Claim 11 (depends on 10)

The medical composition of claim 10, further comprising:
a therapeutically effective amount of remdesivir.

### Claim 12 (depends on 1)

A method for treating a subject suffering from COVID-19, comprising:
administering to the subject in need of the medical composition of claim 1

### Claim 13 (depends on 1)

A method for treating a subject suffering from COVID-19, comprising:
administering to the subject in need of the medical composition of claim 1
